AQUA Dermatology

AQUA Dermatology

AQUA Dermatology represents a classic healthcare private equity roll-up, acquiring independent dermatology practices and integrating them under a single operational and management platform. Headquartered in Palm Beach Gardens, Florida, the firm's strategy targets a fragmented market of physician-owned clinics where scale can yield significant operational efficiencies, centralized billing, and purchasing power. The Southeastern US serves as its core geography, with practices folded into a unified brand offering general dermatology, surgical dermatology, and cosmetic services. The firm's deployment model is direct acquisition and partnership with dermatologists, typically retaining physician founders post-close to maintain clinical leadership while centralizing administrative functions. Asset-class exposure is concentrated in private equity with a singular healthcare services focus. AQUA's roll-up playbook mirrors other sponsor-backed physician practice management (PPM) companies, targeting a specialty with favorable demographic tailwinds and high rates of elective cash-pay procedures. The firm doesn't operate as a fund or family office — it is an operating company capitalized by a private equity sponsor. As a sponsor-backed consolidator, scale is the primary metric. AQUA grows its footprint through bolt-on acquisitions, adding providers and locations to densify existing markets. The firm's back-end integration covers revenue cycle management, compliance, and marketing, allowing acquired physicians to focus on patient volume. Structural differentiation lies in its single-specialty focus within a PPM model — a narrower bet than multi-specialty consolidators, but one that can build deeper referral networks and brand recognition within dermatology specifically. AQUA's structural differentiator is its position in the dermatology PPM wave — a subsector that has seen significant PE interest due to dermatology's blend of medical necessity and cosmetic cash-pay revenue streams. The firm's future is tied to the standard PE consolidation lifecycle: platform building, multiple bolt-ons, operational improvements, and eventual recapitalization or sale to a larger sponsor. The key governance question for any allocator evaluating an investment in the sponsor behind AQUA is how earn-out structures and physician retention are managed post-acquisition.